内毒素 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-08. Anything still debated is marked as such rather than presented as settled.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or loose powder |
| Solubility | Freely soluble in water | Salt form dissolves readily in aqueous buffer |
| Storage (lyophilized) | 2 to 8 °C | Protect from light and moisture |
| Common purity method | Reversed-phase HPLC | Reported as peak-area percentage |
| Identity confirmation | Electrospray mass spectrometry | Measured mass compared with theoretical value |
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
==== MeSH D12.776.467.100.800 – vascular endothelial growth factors ==== MeSH D12.776.467.100.800.200 – vascular endothelial growth factor a MeSH D12.776.467.100.800.300 – vascular endothelial growth factor b MeSH D12.776.467.100.800.400 – vascular endothelial growth factor c MeSH D12.776.467.100.800.500 – vascular endothelial growth factor d MeSH D12.776.467.100.800.600 – vascular endothelial growth factor, endocrine-gland-derived
This has been supported by several organizations, including the Multidisciplinary Association for Psychedelic Studies (MAPS), the Beckley Foundation, the Heffter Research Institute, and the Albert Hofmann Foundation, which exist to fund, encourage, and coordinate research into the medicinal and spiritual uses of LSD and related psychedelics. New clinical LSD experiments in humans started in 2009 for the first time in 35 years. As the drug is illegal in many areas of the world, potential medical uses have historically been difficult to study. Investigational uses of LSD include the treatment of alcoholism, anxiety, and depression, among other conditions. Another use is alleviation of anxiety in terminally ill cancer patients. A single dose of LSD may temporarily reduce alcohol abuse and some psychiatric symptoms, but evidence is limited and unreliable due to methodological flaws and unclear causation. In 2024, the FDA designated a form of LSD as a breakthrough therapy to treat generalized anxiety disorder which is being developed by MindMed. A study published by the Journal of the American Medical Association in September, 2025 explored the optimal dose of LSD to lower patients' anxiety. The study was conducted by the pharmaceutical company MindMed. The researchers compared how LSD doses of 25 μg, 50 μg, 100 μg, 200 μg, or placebo impacted anxiety scores among study participants. The results of the study found that 100 μg was the optimal dose to reduce anxiety among the studied patients.
== Partnerships == Over the years, Antibody Solutions has had strategic agreements with a range of life science companies, including Open Monoclonal Technology, Inc. (OMT), Reflexion Pharmaceuticals, Guava Technologies, Single-Cell Technologies, Trianni, Harbour Antibodies, OmniAb and Alloy Therapeutics.
Sources: en.wikipedia.org
=== KdV-SIR equation === Based on the classical SIR model, a Korteweg-de Vries (KdV)–SIR equation and its analytical solution have been proposed to illustrate the fundamental dynamics of an epidemic wave, the dependence of solutions on parameters, and the dependence of predictability horizons on various types of solutions. The KdV-SIR equation is written as follows:
6 September: The Tāmaki Makaurau by-election is won by Te Pāti Māori candidate Oriini Kaipara. The Sealord Group proposes closing its coated fish factory in Nelson, potentially affecting 79 jobs. 7 September – During the New Zealand First party's annual conference held at Palmerston North, party leader Winston Peters campaigns on increasing compulsory KiwiSaver contributions to ten percent and requiring migrants to sign a values statement. Pro-greyhound racing and Palestinian solidarity protesters picket the event. 8 September: Fugitive father Tom Phillips is shot dead during a confrontation with Police in Piopio, Waikato. Police take one of his children into custody and launch a search for the remaining two unaccompanied minors. By evening, police find the two remaining children safe at a remote campsite. ANZ Bank New Zealand agrees to pay a record fine of NZ$3.25 million to the New Zealand Government after admitting it had breached fair dealing laws twice between 2012 and 2023. The murder trial of Korean mother Hakyung Yee commences, who is facing murder charges for the deaths of her two children. The primary school teachers' union, the New Zealand Educational Institute, rejects the Government's latest pay offer and commences voting on strike action. 9 September – Voting commences in the 2025 local elections. 10 September – The Court of Appeal of New Zealand declines to quash Scott Watson's convictions for the murders of Ben Smart and Olivia Hope, concluding that there had been no "miscarriage of justice" in relation to the prosecution's hair evidence and Mr.
== Works == Macleod was a prolific writer. His first academic article was a paper on phosphorus content in muscles published in 1899. During his career he authored or co-authored over 200 papers and eleven books. Among them are:
== Examples == The following is a list of human proteins containing the protein kinase domain: AAK1 ; AATK ; ABL1 ; ABL2 ; ACVR1 ; ACVR1B ; ACVR1C ; ACVR2A ; ACVR2B ; ACVRL1 ; AKT1 ; AKT2 ; AKT3 ; ALK ; AMHR2 ; ANKK1 ; ARAF ; AURKA ; AURKB ; AURKC ; AXL ; BLK ; BMP2K ; BMPR1A ; BMPR1B ; BMPR2 ; BMX ; BRAF ; BRSK1 ; BRSK2 ; BTK ; BUB1 ; BUB1B ; CAMK1 ; CAMK1D ; CAMK1G ; CAMK2A ; CAMK2B ; CAMK2D ; CAMK2G ; CAMK4 ; CAMKK1 ; CAMKK2 ; CAMKV ; CASK ; CDC42BPA ; CDC42BPB ; CDC42BPG ; CDC7 ; CDK1 ; CDK10 ; CDK11A ; CDK11B ; CDK12 ; CDK13 ; CDK14 ; CDK15 ; CDK16 ; CDK17 ; CDK18 ; CDK19 ; CDK2 ; CDK20 ; CDK3 ; CDK4 ; CDK5 ; CDK6 ; CDK7 ; CDK8 ; CDK9 ; CDKL1 ; CDKL2 ; CDKL3 ; CDKL4 ; CDKL5 ; CHEK1 ; CHEK2 ; CHUK ; CIT ; CLK1 ; CLK2 ; CLK3 ; CLK4 ; CSF1R ; CSK ; CSNK1A1 ; CSNK1A1L ; CSNK1D ; CSNK1E ; CSNK1G1 ; CSNK1G2 ; CSNK1G3 ; CSNK2A1 ; CSNK2A2 ; CSNK2A3 ; DAPK1 ; DAPK2 ; DAPK3 ; DCLK1 ; DCLK2 ; DCLK3 ; DDR1 ; DDR2 ; DMPK ; DSTYK ; DYRK1A ; DYRK1B ; DYRK2 ; DYRK3 ; DYRK4 ; EGFR ; EIF2AK1 ; EIF2AK2 ; EIF2AK3 ; EIF2AK4 ; EPHA1 ; EPHA10 ; EPHA2 ; EPHA3 ; EPHA4 ; EPHA5 ; EPHA6 ; EPHA7 ; EPHA8 ; EPHB1 ; EPHB2 ; EPHB3 ; EPHB4 ; EPHB6 ; ERBB2 ; ERBB3 ; ERBB4 ; ERN1 ; ERN2 ; FER ; FES ; FGFR1 ; FGFR2 ; FGFR3 ; FGFR4 ; FGR ; FLT1 ; FLT3 ; FLT4 ; FRK ; FYN ; GAK ; GRK1 ; GRK2 ; GRK3 ; GRK4 ; GRK5 ; GRK6 ; GRK7 ; GSG2 ; GSK3A ; GSK3B ; GUCY2C ; GUCY2D ; GUCY2F ; HCK ; HIPK1 ; HIPK2 ; HIPK3 ; HIPK4 ; HUNK ; ICK ; IGF1R ; IKBKB ; IKBKE ; ILK ; INSR ; INSRR ; IRAK1 ; IRAK2 ; IRAK3 ; IRAK4 ; ITK ; JAK1 ; JAK2 ; JAK3 ; KALRN ; KDR ; KIT ; KSR1 ; KSR2 ; LATS1 ; LATS2 ; LCK ; LIMK1 ; LIMK2 ; LMTK2 ; LMTK3 ; LRRK1 ; LRRK2 ; LTK ; LYN ; MAK ; MAP2K1 ; MAP2K2 ; MAP2K3 ; MAP2K4 ; MAP2K5 ; MAP2K6 ; MAP2K7 ; MAP3K1 ; MAP3K10 ; MAP3K11 ; MAP3K12 ; MAP3K13 ; MAP3K14 ; MAP3K15 ; MAP3K19 ; MAP3K2 ; MAP3K20 ; MAP3K21 ; MAP3K3 ; MAP3K4 ; MAP3K5 ; MAP3K6 ; MAP3K7 ; MAP3K8 ; MAP3K9 ; MAP4K1 ; MAP4K2 ; MAP4K3 ; MAP4K4 ; MAP4K5 ; MAPK1 ; MAPK10 ; MAPK11 ; MAPK12 ; MAPK13 ; MAPK14 ; MAPK15 ; MAPK3 ; MAPK4 ; MAPK6 ; MAPK7 ; MAPK8 ; MAPK9 ; MAPKAPK2 ; MAPKAPK3 ; MAPKAPK5 ; MARK1 ; MARK2 ; MARK3 ; MARK4 ; MAST1 ; MAST2 ; MAST3 ; MAST4 ; MASTL ; MATK ; MELK ; MERTK ; MET ; MINK1 ; MKNK1 ; MKNK2 ; MLKL ; MOK ; MOS ; MST1R ; MUSK ; MYLK ; MYLK2 ; MYLK3 ; MYLK4 ; MYO3A ; MYO3B ; NEK1 ; NEK10 ; NEK11 ; NEK2 ; NEK3 ; NEK4 ; NEK5 ; NEK6 ; NEK7 ; NEK8 ; NEK9 ; NIM1K ; NLK ; NPR1 ; NPR2 ; NRBP1 ; NRBP2 ; NRK ; NTRK1 ; NTRK2 ; NTRK3 ; NUAK1 ; NUAK2 ; OBSCN ; OXSR1 ; PAK1 ; PAK2 ; PAK3 ; PAK4 ; PAK5 ; PAK6 ; PAN3 ; PASK ; PBK ; PDGFRA ; PDGFRB ; PDIK1L ; PDPK1 ; PDPK2P ; PEAK1 ; PEAK3 ; PHKG1 ; PHKG2 ; PIK3R4 ; PIM1 ; PIM2 ; PIM3 ; PINK1 ; PKDCC ; PKMYT1 ; PKN1 ; PKN2 ; PKN3 ; PLK1 ; PLK2 ; PLK3 ; PLK4 ; PLK5 ; PNCK ; POMK ; PRKAA1 ; PRKAA2 ; PRKACA ; PRKACB ; PRKACG ; PRKCA ; PRKCB ; PRKCD ; PRKCE ; PRKCG ; PRKCH ; PRKCI ; PRKCQ ; PRKCZ ; PRKD1 ; PRKD2 ; PRKD3 ; PRKG1 ; PRKG2 ; PRKX ; PRKY ; PRPF4B ; PSKH1 ; PSKH2 ; PTK2 ; PTK2B ; PTK6 ; PTK7 ; PXK ; RAF1 ; RET ; RIOK1 ; RIOK2 ; RIOK3 ; RIPK1 ; RIPK2 ; RIPK3 ; RIPK4 ; RNASEL ; ROCK1 ; ROCK2 ; ROR1 ; ROR2 ; ROS1 ; RPS6KA1 ; RPS6KA2 ; RPS6KA3 ; RPS6KA4 ; RPS6KA5 ; RPS6KA6 ; RPS6KB1 ; RPS6KB2 ; RPS6KC1 ; RPS6KL1 ; RSKR ; RYK ; SBK1 ; SBK2 ; SBK3 ; SCYL1 ; SCYL2 ; SCYL3 ; SGK1 ; SGK2 ; SGK223 ; SGK3 ; SIK1 ; SIK1B ; SIK2 ; SIK3 ; SLK ; SNRK ; SPEG ; SRC ; SRMS ; SRPK1 ; SRPK2 ; SRPK3 ; STK10 ; STK11 ; STK16 ; STK17A ; STK17B ; STK24 ; STK25 ; STK26 ; STK3 ; STK31 ; STK32A ; STK32B ; STK32C ; STK33 ; STK35 ; STK36 ; STK38 ; STK38L ; STK39 ; STK4 ; STK40 ; STKLD1 ; STRADA ; STRADB ; STYK1 ; SYK ; TAOK1 ; TAOK2 ; TAOK3 ; TBCK ; TBK1 ; TEC ; TEK ; TESK1 ; TESK2 ; TEX14 ; TGFBR1 ; TGFBR2 ; TIE1 ; TLK1 ; TLK2 ; TNIK ; TNK1 ; TNK2 ; TNNI3K ; TP53RK ; TRIB1 ; TRIB2 ; TRIB3 ; TRIO ; TSSK1B ; TSSK2 ; TSSK3 ; TSSK4 ; TSSK6 ; TTBK1 ; TTBK2 ; TTK ; TTN ; TXK ; TYK2 ; TYRO3 ; UHMK1 ; ULK1 ; ULK2 ; ULK3 ; ULK4 ; VRK1 ; VRK2 ; VRK3 ; WEE1 ; WEE2 ; WNK1 ; WNK2 ; WNK3 ; WNK4 ; YES1 ; ZAP70
Sources: en.wikipedia.org
Three-quarters of sickle cell cases occur in Africa. A World Health Organization report dated 2006 estimated that around 2% of newborns in Nigeria are affected by sickle cell anaemia, giving a total of 150,000 affected children born every year in Nigeria alone. The carrier frequency ranges between 10 and 40% across equatorial Africa, decreasing to 1–2% on the North African coast and <1% in South Africa. In the West African countries of Ghana and Nigeria, the frequencies can vary from 15 to 30%. In Nigeria, 24% of the population carries the gene, and 20 per 1,000 newborns are born with the disease, or 150,000 annually. Uganda has the fifth-highest sickle cell disease burden in Africa. One study indicates that 20,000 babies per year, or 0.7% of the total, are born with sickle cell disease, and 13.3% carry the trait. In Uganda, carrier frequency of the trait varies strongly across tribal lines: among the Baamba, it reaches 45%.
Substrate-level phosphorylation: 2 ATP from glycolysis + 2 ATP (directly GTP) from Krebs cycle Oxidative phosphorylation 2 NADH+H+ from glycolysis: 2 × 1.5 ATP (if glycerol phosphate shuttle transfers hydrogen atoms) or 2 × 2.5 ATP (malate-aspartate shuttle) 2 NADH+H+ from the oxidative decarboxylation of pyruvate and 6 from Krebs cycle: 8 × 2.5 ATP 2 FADH2 from the Krebs cycle: 2 × 1.5 ATP Altogether this gives 4 + 3 (or 5) + 20 + 3 = 30 (or 32) ATP per molecule of glucose These figures may still require further tweaking as new structural details become available. The above value of 3 H+ / ATP for the synthase assumes that the synthase translocates 9 protons, and produces 3 ATP, per rotation. The number of protons depends on the number of c subunits in the Fo c-ring, and it is now known that this is 10 in yeast Fo and 8 for vertebrates. Including one H+ for the transport reactions, this means that synthesis of one ATP requires 1 + 10/3 = 4.33 protons in yeast and 1 + 8/3 = 3.67 in vertebrates. This would imply that in human mitochondria the 10 protons from oxidizing NADH would produce 2.72 ATP (instead of 2.5) and the 6 protons from oxidizing succinate or ubiquinol would produce 1.64 ATP (instead of 1.5). This is consistent with experimental results within the margin of error described in a recent review. The total ATP yield in ethanol or lactic acid fermentation is only 2 molecules coming from glycolysis, because pyruvate is not transferred to the mitochondrion and finally oxidized to the carbon dioxide (CO2), but reduced to ethanol or lactic acid in the cytoplasm.
=== Contraindications === Ketosis induced by a ketogenic diet should not be pursued by people with pancreatitis because of the high dietary fat content. Ketosis is also contraindicated in pyruvate carboxylase deficiency, porphyria, and other rare genetic disorders of fat metabolism.
The health of the dental pulp can be established by a variety of diagnostic aids which test either the blood supply to a tooth (Vitality Test) or the sensory response of the nerves within the root canal to specific stimuli (Sensitivity Test). Although less accurate, sensitivity tests, such as Electric Pulp Tests or Thermal Tests, are more routinely used in clinical practice than vitality testing, which requires specialised equipment. A healthy tooth is expected to respond to sensitivity testing with a short, sharp burst of pain which subsides when the stimulus is removed. An exaggerated or prolonged response to sensitivity testing indicates that the tooth has some degree of symptomatic pulpitis. A tooth that does not respond at all to sensitivity testing may have become necrotic.
==== Cancer immunotherapy ==== In 1995, Robert Conry demonstrated that intramuscular injection of naked RNA encoding carcinoembryonic antigen elicited antigen-specific antibody responses. Then, it was elaborated by demonstrating that dendritic cells(DCs) exposed to mRNA coding for specific antigens or to total mRNA extracted from tumor cells and injected into tumor-bearing mice induced T cell immune responses and inhibited the growth of tumors. Then, researchers started to approach mRNA transfected DCs using vaccines based on ex vivo IVT mRNA-transfected DCs. Meanwhile, Argos Therapeutics had initiated a Phase III clinical trial using DCs with advanced renal cell carcinoma in 2015 (NCT01582672) but it was terminated due to the lack of efficacy. For further application, IVT mRNA was optimized for in situ transfections of DCs in vivo. It improved the translation efficiency and stability of IVT mRNA and enhanced the presentation of the mRNA-encoded antigen on MHC class I and II molecules. Then, they found out that the direct injection of naked IVT mRNA into lymph nodes was the most effective way to induce T cell responses. Based on this discovery, first-in-human testing of the injection of naked IVT mRNA encoding cancer antigens by BioNTech has started with patients with melanoma (NCT01684241). Recently, the new cancer immunotherapy, the combining of self-delivering RNA(sd-rxRNA) and adoptive cell transfer(ACT) therapy, was invented by RXi Pharmaceuticals and the Karolinska Institute.
Sources: en.wikipedia.org
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.
Mass spectrometry serves as the primary identity check, since the measured mass must agree with the theoretical value for a 44-residue sequence. Chromatographic retention time and peptide mapping supply supporting evidence.
Certificates of analysis and independent testing tie a specific lot to specific measured results. Without that link, purity and identity claims rest on the supplier's own statement rather than on verifiable data.
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.